| Bioactivity | Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research[1][2][3]. |
| Invitro | Ivonescimab 可与 PD-1 和 VEGFA 结合，EC50 分别为 0.06 和 0.036 nM[2]。Ivonescimab 可与 VEGF 形成可溶性复合物 (通过 SEC-HPLC 检测)[2]。 |
| Name | Ivonescimab |
| CAS | 2428381-53-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Coward J, et al. Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study. Journal for Immuno Therapy of Cancer 2021;9: [2]. Zhong T, et al. AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies. Journal for Immuno Therapy of Cancer. 2022;10: [3]. Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. Journal for Immuno Therapy of Cancer. 2022;10:e005517. |